NYSE:TEVAPharmaceuticals
How Investors Are Reacting To Teva (TEVA) AUSTEDO Real‑World Data On Tardive Dyskinesia Improvement
In early June 2026, Teva Pharmaceutical Industries reported new clinical data from three studies showing that AUSTEDO and AUSTEDO XR improved tardive dyskinesia symptoms, daily functioning, and diagnosis rates when presented at Psych Congress Elevate in Las Vegas.
The findings, including real-world evidence from the IMPACT-TD Registry and long-term outcomes from the RIM-TD study, suggest that sustained treatment and caregiver education can meaningfully enhance recognition and management of...